Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Free Cash Flow (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Free Cash Flow for 7 consecutive years, with -$14.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 36.21% to -$14.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$55.8 million through Dec 2025, down 216.32% year-over-year, with the annual reading at -$51.8 million for FY2025, 24.66% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$14.9 million at Outlook Therapeutics, down from -$12.4 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$11.0 million in Q4 2024, with the low at -$16.6 million in Q1 2025.